Zimmer Biomet Holdings, Inc. is a publicly traded medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
In 2001, Zimmer was spun off from Bristol-Myers Squibb and began trading on the New York Stock Exchange, on August 7, under the ticker symbol “ZMH”.[2] In November 2011, the company acquired ExtraOrtho, Inc. (ExtraOrtho). In January 2012, the company acquired Reno, Nevada-based Synvasive Technology, Inc.[3] On June 29, 2015, the company changed the ticker symbol to "ZBH" to reflect its acquisition of Biomet.[4]
On January 12, 2017, Zimmer Biomet announced a resolution with the DOJ and the SEC in which it agreed to pay a fine of approximately $30.5 million, an amount which would not affect its 2017 outlook.[5]
Zimmer Biomet was established in 1927 by Justin O. Zimmer (1884–1951)[6] in Warsaw, Indiana.[7][8] Then they began sending implants into the field excessively out of print. Just one example with a dimension off by approx .125".[citation needed]
On April 24, 2014, it was announced that Zimmer had agreed to purchase Biomet Inc. for $13.4 billion.[9] In October 2014, however, it was announced that the EU's antitrust regulators had opened an extensive investigation into Zimmer's bid for Biomet due to concern that it would substantially lessen competition in certain markets.[10] In March 2016, European Commission (“EC”) conditionally cleared Zimmer's proposed acquisition of Biomet, Inc.[11][12] and on June 24, 2015, Zimmer completed its acquisition of Biomet forming Zimmer Biomet Holdings.[4]
In October 2014, the company announced it would acquire ETEX Holdings, Inc.[13][14]
In March 2016, Zimmer Biomet announced it would acquire Ortho Transmission, LLC.[15] The company also announced it would acquire sports medicine company, Cayenne Medical, Inc.[16][17] Later in the same year the company acquired medical device manufacturer, LDR Holding Corporation for $37 per share ($1 billion in total),[18] merging it into their Spine division.[19][20] In July, the company acquired French surgical robotics company Medtech.[21] In August, the company announced it was acquiring Delaware-based CD Diagnostics,[22] a diagnostics company developing immunoassays and biomarker testing.[23] In September, Zimmer announced the acquisition of Clinical Graphics, B.V.[24]
In January 2023, the company announced its intention to acquire Embody, Inc. for $155 million (plus a potential $120 million in milestones).[25]
Products
Zimmer designs, develops, manufactures and markets orthopedics products, including knee, hip, shoulder, elbow, foot and ankle artificial joints and dental prostheses. Zimmer has operations in more than 40 countries around the world (US, Australia, Austria, Belgium, Canada, China, Czech Republic, Finland, France, Germany, India, Ireland, Israel, Italy, Japan, Latin America, Netherlands, Brasil, Poland, Portugal, Russia, South Africa, Spain etc.) and sells products in more than 100 countries.[26]
Acquisition history
The following is an illustration of the company's major mergers, acquisitions and historical predecessors:
Biomet-Merck Joint Venture (Acq 2004, renamed Biomet Europe Group)
Ortho Transmission, LLC (Acq 2016)
Cayenne Medical, Inc. (Acq 2016)
LDR Holding Corporation (Acq 2016)
CD Diagnostics (Acq 2016)
Clinical Graphics, B.V. (Acq 2016)
Embody, Inc. (Acq 2023)
Company data
Zimmer's 2022 sales were approximately $6.94 billion. The company has approximately 18,000 employees worldwide.[1]
Leadership
David C. Dvorak, was president and CEO[27] from May 1, 2007, to July 11, 2017.[28]
Dan Florin, Interim President and CEO from July 11, 2017, to December 19, 2017.[29]
Bryan C. Hanson, President and CEO from December 19, 2017[29] to August 22, 2023.
Ivan Tornos, President and CEO from August 22, 2023 to current.
Recognition
In 2016, the company was recognized on the Fortune 500 list for the first time, ranking in position #431.[30] Since then, it has been on the list for three straight years.[31] As of 2018, the company is ranked 361st on the list.[32]
Criticism
During the 2022 Russian invasion of Ukraine, Zimmer Biomet continued to sell to the Russian market. Research from Yale University updated on April 28, 2022, identifying how companies were reacting to Russia's invasion identified Zimmer Biomet as continuing business-as-usual in Russia: companies defying demands for exit/reduction of activities.[33]
US$6.94 billion (2022)
US$696 million (2022)
